TrialsgrambetaRCTs are beautiful

KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

This guideline cites 7 of the 58 landmark trials in our Nephrology register.

KDIGO 2021 makes two moves at once: it lowers the systolic target in CKD to <120 mmHg, and it makes that target conditional on standardised office measurement — the technique used in SPRINT, not the one used in most clinics. Renin–angiotensin-system inhibitors remain first-line in albuminuric CKD, diabetic and non-diabetic alike, while dual RAS blockade is explicitly ruled out. Kidney-transplant recipients get a separate, higher target. The register's trials behind the target and the drug choice are grouped below.

Blood-pressure targets in CKD2

  • 2017SPRINT-CKD⁠Nephrology · CKD · Blood-pressure targetsIn 2,646 participants with chronic kidney disease, an intensive systolic-BP target below 120 mmHg reduced all-cause mortality compared with a target below 140 mmHg.HR 0.72CI 0.53-0.99Read →
  • 2002AASK⁠Nephrology · CKD · RAAS blockadeIn 1,094 Black patients with hypertensive nephrosclerosis, ramipril slowed kidney-disease progression compared with amlodipine or metoprolol.Read →

RAS blockade in diabetic kidney disease3

  • 2001RENAAL Core⁠Nephrology · CKD · RAAS blockadeIn 1,513 patients with type 2 diabetes and nephropathy, losartan reduced the composite of creatinine doubling, ESRD or death compared with placebo.Read →
  • 2001IDNT Core⁠Nephrology · CKD · RAAS blockadeIn 1,715 patients with type 2 diabetes and nephropathy, irbesartan reduced progression of the renal composite compared with amlodipine or placebo.Read →
  • 1993Captopril-DN Core⁠Nephrology · CKD · RAAS blockadeIn 409 patients with type 1 diabetes and diabetic nephropathy, captopril reduced doubling of serum creatinine compared with placebo.HR 0.5295% CI 0.31-0.84Read →

RAS blockade in non-diabetic proteinuric CKD1

  • 1997REIN⁠Nephrology · CKD · RAAS blockadeIn 352 patients with non-diabetic proteinuric chronic kidney disease, ramipril slowed GFR decline and progression to ESRD compared with placebo.Read →

Dual RAS blockade: ruled out1

  • 2013VA NEPHRON-D⁠Nephrology · CKD · RAAS blockadeIn 1,448 patients with type 2 diabetes and albuminuric CKD, dual blockade with losartan plus lisinopril did not reduce the renal composite compared with losartan alone.HR 0.8895% CI 0.70-1.12Read →

Cited landmark trials not yet in the register4

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 1994MDRD

    Lower blood-pressure target slowed progression only in proteinuric CKD.

  • 1998HOT

    Diastolic target trial; little benefit below 85 mmHg outside diabetes.

  • 2008ONTARGET

    Dual RAS blockade increased renal adverse events without benefit.

  • 2012ALTITUDE

    Aliskiren on top of RAS blockade — stopped early for harm.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.